3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
14
Nivolumab
6
Carboplatin
5
sargramostim
4
Fluorouracil
4
Drug Therapy
4
Thiotepa
3
Sorafenib
3
Radiotherapy
3
Ipilimumab
3
Interferon-alpha
3
Gemcitabine
3
Filgrastim
3
Counseling
3
Cetuximab
3
liposomal doxorubicin
2
ixabepilone
2
entinostat
2
cemiplimab
2
belinostat
2
atezolizumab
2
Temozolomide
2
Surveys and Questionnaires
2
Sirolimus
2
Psychiatric Rehabilitation
2
Polymerase Chain Reaction
2
Paclitaxel
2
Methods
2
Melphalan
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Blood Component Removal
×
Gastrointestinal
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled